Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: Mucosal healing has become the treatment goal in patients with ulcerative colitis (UC) and Crohn's disease (CD). Whether low fecal calprotectin levels and histological healing combined with mucosal healing is associated with a further reduced risk of relapses is unknown. METHODS: Patients with CD, UC or inflammatory bowel disease-unclassified (IBD-U) scheduled for surveillance colonoscopy collected a stool sample prior to bowel cleansing. Only patients with mucosal healing (MAYO endoscopic score of 0) were included. Fecal calprotectin was measured using a quantitative enzyme-linked immunosorbent assay (R-Biopharm, Germany). Biopsies were obtained from four colonic segments, and histological disease severity was assessed using the Geboes scoring system. Patients were followed until the last outpatient clinic visit or the development of a relapse, which was defined as IBD-related hospitalization, surgery or step-up in IBD medication. RESULTS: Of the 164 patients undergoing surveillance colonoscopy, 92 patients were excluded due to active inflammation or missing biopsies. Of the remaining 72 patients (20 CD, 52 UC or IBD-U), six patients (8%) relapsed after a median follow-up of 11 months (range 5-15 months). Median fecal calprotectin levels at baseline were significantly higher for patients who relapsed compared with patients who maintained remission (284 mg/kg vs. 37 mg/kg. p < 0.01). Fecal calprotectin below 56 mg/kg was found to optimally predict absence of relapse during follow-up with 64% sensitivity, 100% specificity, 100% negative predictive value and 20% positive predictive value. The presence or absence of active inflammation determined by Geboes cut-off score of 3.1 was less strongly associated with the risk of relapse (64% sensitivity, 33% specificity, 9% negative predictive value and 92% positive predictive value. CONCLUSION: Low calprotectin levels identify IBD patients who remain in stable remission during follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Tibble, J. A., Sigthorsson, G., Bridger, S., Fagerhol, M. K., & Bjarnason, I. (2000) · Gastroenterology · doi:10.1053/gast.2000.8523 · Cited by 759 · cited 1×
“UC/IBD-unclassified patients (51) CD patients (21)”
Cellier, C., Sahmoud, T., Froguel, E., Adenis, A., Belaiche, J., Bretagne, J. F., Florent, C., Bouvry, M., Mary, J. Y., & Modigliani, R. (1994) · Gut · doi:10.1136/gut.35.2.231 · Cited by 430 · cited 1×
“4,5 Therefore, ileocolonoscopy is the current gold standard for the assessment of intestinal inflammation in IBD patients, but this procedure is invasive and costly.”
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Bryant, R. V., Burger, D. C., Delo, J., Walsh, A. J., Thomas, S., von Herbay, A., Buchel, O. C., White, L., Brain, O., Keshav, S., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309598 · Cited by 443
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis
Mohammed Vashist, N., Samaan, M., Mosli, M. H., Parker, C. E., MacDonald, J. K., Nelson, S. A., Zou, G., Feagan, B. G., Khanna, R., & Jairath, V. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011450.pub2 · Cited by 277
Current best practice for disease activity assessment in IBD
Walsh, A. J., Bryant, R. V., & Travis, S. P. L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.128 · Cited by 223
Pimentel, M., Morales, W., Rezaie, A., Marsh, E., Lembo, A., Mirocha, J., Leffler, D. A., Marsh, Z., Weitsman, S., Chua, K. S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126438 · Cited by 148
“However, there are pitfalls with the calprotectin in that patients in remission of their IBD may be negative and essentially functions to rule in active ongoing IBD [44].”
Background
Metadata
- Authors
- Mooiweer, E., Severs, M., Schipper, M. E. I., Fidder, H. H., Siersema, P. D., Laheij, R. J. F., & Oldenburg, B.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-05
- Volume
- 9
- Issue
- 1
- Pages
- 50-55
- ISSN
- 1873-9946 (ISSN-L)
- 1876-4479
- OpenAlex
- W2161266130
- Cited by
- 110
- References
- 3
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission. https://app.cochat.ai/papers/10.1093/ecco-jcc/jju003
- The paper
- Mooiweer, E., Severs, M., Schipper, M. E. I., Fidder, H. H., Siersema, P. D., Laheij, R. J. F., & Oldenburg, B. (2015). Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jju003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.